News | April 07, 2025
Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
In 2023, Endox had revenues of approximately SEK 65 million
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Subscribe To Our Newsletter & Stay Updated
